Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.54 |
| ▸ | PDCD1LG2 | Q9BQ51 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29884047 | 0.91 | HTR2A (0.55) | HTR2AHTR2CCD274PDCD1LG2PDCD1 | |
| SCHEMBL10863438 | 0.84 | HTR2A (0.57) | HTR2AHTR2CCD274PDCD1KDM1A | |
| SCHEMBL10483983 | 0.82 | HTR2A (0.55) | HTR2AHTR2CCD274PDCD1KDM1A | |
| SCHEMBL28223887 | 0.79 | ALDH1A1 (0.50) | CD274PDCD1LG2ALDH1A1PDCD1KDM4E | |
| SCHEMBL6047280 | 0.78 | KDM1A (0.54) | HTR2AHTR2CCD274PDCD1KDM1A | |
| SCHEMBL5780541 | 0.78 | SLC13A5 (0.54) | HTR2AHTR2CALDH1A1L3MBTL1KDM1A | |
| SCHEMBL18440 | 0.78 | MEN1 (0.60) | HTR2AHTR2CALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL31365171 | 0.78 | MEN1 (0.60) | HTR2AHTR2CALDH1A1KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5900888 | 0.76 | MEN1 (0.58) | HTR2AHTR2CALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL23017040 | 0.76 | ALDH1A1 (0.46) | HTR2AHTR2CCD274PDCD1LG2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | HTR2A 2366/4885HTR2C 1385/4885CD274 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.